Abstract No. 124 Systemic therapy in advanced hepatocellular carcinoma: where are we heading?

Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer in the world and third, in cancer related mortality. Only 20% HCC are early HCCs that are eligible for therapies such as resection, liver transplantation, and local ablation due to advanced stage, tumor burden, lack of liver donors and liver dysfunction. The majority of HCCs are treated with palliative therapy, which includes Transarterial chemoembolization (TACE) and systemic therapy, while transarterial radioembolization still struggles to find a place in evidence-based treatment.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Source Type: research